Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer
cells when they are put back in the body. This may be an effective treatment for patients
undergoing a stem cell transplant for multiple myeloma.
PURPOSE: This phase I/II trial is studying the side effects of activated white blood cells
and to see how well they work in treating patients who are undergoing a stem cell transplant
for newly diagnosed stage II or stage III multiple myeloma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins